UK Pips EU To The Post With ‘Project Orbis’ Approval For Tagrisso
EU Early-Use Approval For AstraZeneca’s NSCLC Drug Imminent
The UK drug regulator, the MHRA, has approved its first product under Project Orbis, the US-led international regulatory collaboration scheme it joined four months ago to speed up access to promising cancer medicines.
You may also be interested in...
Patients in England with non-small cell lung cancer will be the first In Europe to be offered Amgen’s KRAS G12C inhibitor.
Industry has paid millions of pounds under the ongoing UK Voluntary Scheme on Branded Medicines Pricing and Access but there are concerns over poor progress with other commitments that were promised under the scheme for managing branded medicine spend by the National Health Service.
The UK has the potential to fulfill its ambition of being a global superpower in life sciences, but it must not get lost in an echo chamber, says a senior MSD executive.